A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination With Doxorubicin vs. Doxorubicin Alone in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

TYPE OF SARCOMA: Locally advanced or metastatic soft tissue sarcoma
DRUG: TH-302 combined with doxorubicin vs. doxorubicin alone
ACCRUAL STATUS: Completed

OVERALL STUDY PRINCIPAL INVESTIGATORS:
William Tap, MD
Memorial Sloan Kettering Cancer Center

CLINICALTRIALS.GOV IDENTIFIER: NCT01440088

FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICALTRIALS.GOV

To learn more about this study or to contact the study research staff: